NASDAQ:COYA Coya Therapeutics (COYA) Stock Price, News & Analysis $6.01 -0.05 (-0.83%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$5.73▼$6.3850-Day Range$4.82▼$7.7052-Week Range$3.21▼$10.69Volume57,614 shsAverage Volume67,033 shsMarket Capitalization$87.85 millionP/E RatioN/ADividend YieldN/APrice Target$16.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Coya Therapeutics alerts: Email Address Coya Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside166.2% Upside$16.00 Price TargetShort InterestHealthy1.14% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.48Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.17) to ($1.26) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.33 out of 5 starsMedical Sector457th out of 910 stocksPharmaceutical Preparations Industry212th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingCoya Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCoya Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Coya Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.14% of the float of Coya Therapeutics has been sold short.Short Interest Ratio / Days to CoverCoya Therapeutics has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Coya Therapeutics has recently decreased by 9.05%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCoya Therapeutics does not currently pay a dividend.Dividend GrowthCoya Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for COYA. Previous Next 2.5 News and Social Media Coverage News SentimentCoya Therapeutics has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Coya Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for COYA on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows1 people have added Coya Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Coya Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.00% of the stock of Coya Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 39.75% of the stock of Coya Therapeutics is held by institutions.Read more about Coya Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Coya Therapeutics are expected to decrease in the coming year, from ($1.17) to ($1.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Coya Therapeutics is -7.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Coya Therapeutics is -7.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCoya Therapeutics has a P/B Ratio of 2.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Coya Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About Coya Therapeutics Stock (NASDAQ:COYA)Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.Read More COYA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart COYA Stock News HeadlinesSeptember 3, 2024 | finance.yahoo.comCoya Therapeutics to Present at Upcoming Healthcare ConferencesSeptember 3, 2024 | finance.yahoo.comHere's Why We're Not At All Concerned With Coya Therapeutics' (NASDAQ:COYA) Cash Burn SituationSeptember 7, 2024 | Weiss Ratings (Ad)America dodged a crisis — next time it could be much worseLegendary financial forecaster, Dr. Martin Weiss, has been warning us about it for months … He believes the next incident could lead to people seeing their bank accounts frozen.August 20, 2024 | marketwatch.comCoya Therapeutics Names Arun Swaminathan Chief ExecutiveAugust 20, 2024 | markets.businessinsider.comCoya Therapeutics Promotes Arun Swaminathan To CEOAugust 12, 2024 | markets.businessinsider.comCOYA Stock Earnings: Coya Therapeutics Misses EPS, Misses Revenue for Q2 2024August 12, 2024 | finance.yahoo.comCoya Therapeutics Provides a Corporate Update and Reports Unaudited Second Quarter 2024 Financial ResultsAugust 4, 2024 | investing.comCoya reports Alzheimer's trial to present at CTAD24September 7, 2024 | Weiss Ratings (Ad)America dodged a crisis — next time it could be much worseLegendary financial forecaster, Dr. Martin Weiss, has been warning us about it for months … He believes the next incident could lead to people seeing their bank accounts frozen.August 2, 2024 | msn.comCoya Therapeutics Blunders on Test ResultsAugust 2, 2024 | businesswire.comCoya Therapeutics Announces that Results from a Double-Blind Placebo-Controlled Study in Alzheimer's Disease will be presented on October 29, 2024 at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) in MadridJune 20, 2024 | businesswire.comCoya Therapeutics Expands Sponsored Research Collaboration with Houston Methodist Research Institute Along with Funding from the Johnson Center for Cellular Therapeutics to Advance Regulatory T Cell Exosome Platform into the ClinicJune 3, 2024 | businesswire.comCoya Therapeutics Announces Acceptance of Peer-Reviewed Manuscript in the Medical Journal: Frontiers in NeurologyMay 28, 2024 | businesswire.comCoya Therapeutics Announces Inclusion in the MSCI USA Micro Cap IndexMay 27, 2024 | investorplace.com7 Biotech Stocks to Put on Your Breakthrough RadarMay 27, 2024 | finance.yahoo.comEXCLUSIVE: Coya Therapeutics, Focused On Neurodegenerative Diseases Has Gained 70% Since IPO; CEO Highlights Efforts On Combination Therapy For Rare DiseasesMay 22, 2024 | finance.yahoo.comCoya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s DiseaseMay 22, 2024 | businesswire.comCoya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer's DiseaseSee More Headlines Receive COYA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Coya Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/12/2024Today9/07/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:COYA CUSIPN/A CIK1835022 Webwww.coyatherapeutics.com Phone800-587-8170FaxN/AEmployees6Year FoundedN/APrice Target and Rating Average Stock Price Target$16.00 High Stock Price Target$18.00 Low Stock Price Target$14.00 Potential Upside/Downside+166.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.85) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,990,000.00 Net MarginsN/A Pretax Margin-98.15% Return on Equity-35.63% Return on Assets-30.96% Debt Debt-to-Equity RatioN/A Current Ratio10.43 Quick Ratio10.43 Sales & Book Value Annual Sales$9.55 million Price / Sales9.20 Cash FlowN/A Price / Cash FlowN/A Book Value$2.32 per share Price / Book2.59Miscellaneous Outstanding Shares14,618,000Free Float12,864,000Market Cap$87.85 million OptionableNot Optionable Beta0.58 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Howard Berman Ph.D. (Age 50)Chairman & CEO Comp: $833.75kDr. Fred Grossman D.O. (Age 62)FAPA, President & Chief Medical Officer Comp: $610.63kMr. David S. Snyder (Age 64)CFO & COO Comp: $610.94kDr. Gregory MacMichael Ph.D. (Age 68)Chief Technical Officer Dr. Michelle Frazier Ph.D.Senior Vice President of Regulatory AffairsMr. Aaron Thome Ph.D.Head of Neuroinflammation PlatformDr. Arun Swaminathan Ph.D.Chief Business Development OfficerMore ExecutivesKey CompetitorsAlvotechNASDAQ:ALVOSutro BiopharmaNASDAQ:STROVoyager TherapeuticsNASDAQ:VYGRNeoleukin TherapeuticsNASDAQ:NLTXSNDLNASDAQ:SNDLView All CompetitorsInstitutional OwnershipRenaissance Technologies LLCBought 16,700 shares on 8/9/2024Ownership: 0.114%Gilbert & Cook Inc.Bought 10,000 shares on 8/1/2024Ownership: 0.068%View All Institutional Transactions COYA Stock Analysis - Frequently Asked Questions How have COYA shares performed this year? Coya Therapeutics' stock was trading at $7.41 at the beginning of the year. Since then, COYA stock has decreased by 18.9% and is now trading at $6.01. View the best growth stocks for 2024 here. How were Coya Therapeutics' earnings last quarter? Coya Therapeutics, Inc. (NASDAQ:COYA) posted its quarterly earnings results on Monday, August, 12th. The company reported ($0.19) earnings per share (EPS) for the quarter. The business had revenue of $3.43 million for the quarter. When did Coya Therapeutics IPO? Coya Therapeutics (COYA) raised $15 million in an IPO on Thursday, December 29th 2022. The company issued 3,050,000 shares at a price of $5.00 per share. Who are Coya Therapeutics' major shareholders? Coya Therapeutics' top institutional investors include Renaissance Technologies LLC (0.11%) and Gilbert & Cook Inc. (0.07%). How do I buy shares of Coya Therapeutics? Shares of COYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:COYA) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coya Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.